MedTrace Logo

A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

NCT07723833 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2026-08-03

No results posted yet for this study

Summary

The purpose of this study is to measure the pharmacokinetics (PK-how the body processes the study drug) of elecoglipron in healthy participants when taken by mouth as different formulations.

Conditions

  • Healthy Participants

Interventions

DRUG

Elecoglipron Reference Formulation Dose A

Elecoglipron tablets will be administered orally.

DRUG

Elecoglipron Test formulation 1 Dose A

Elecoglipron tablets will be administered orally.

DRUG

Elecoglipron Reference Formulation Dose B

Elecoglipron tablets will be administered orally.

DRUG

Elecoglipron Test formulation 1 Dose B

Elecoglipron tablets will be administered orally.

DRUG

Elecoglipron Test formulation 2 Dose A

Elecoglipron tablets will be administered orally.

DRUG

Elecoglipron Test formulation 2 Dose B

Elecoglipron tablets will be administered orally.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-27
Primary Completion
2026-11-18
Completion
2026-11-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07723833 on ClinicalTrials.gov